Table 2.
Investigations results of 288 children managed with COVID-19 infection between 1st March and 31st May 2020.
| n (%) | |
|---|---|
| Laboratory findings | |
| Total white blood cell count (x109/L) | 7.4 [5.4, 9.6] |
| Hemoglobin concentration (g/L) | 125 [116, 133] |
| Platelet count (x109/L) | 87 [255, 372] |
| platelet count <150 x 109/L | 208 [72.2] |
| Neutrophils count (x109/L) | 2.3 [1.6, 3.6] |
| Ferritin (ng/mL) | 57 [37, 85] |
| Lactic dehydrogenase (U/L) | 245 [208, 290] |
| Alanine aminotransferase (U/L) | 16 [12, 21] |
| Aspartate aminotransferase (U/L) | 28 [21, 34] |
| International normalized ratio (INR) | 1.07 ± 0.1 |
| Prothrombin time (seconds) | 11.5 ± 0.7 |
| Imaging | |
| Chest X-ray done to all 288/288 (100) Chest X-ray opacities | 19 (9) |
| Right-sided | 7 (50) |
| Left-sided | 1 (7) |
| Bilateral | 6 (43) |
| Abnormal computed tomography | 1 (6) |
| Microbiology | |
| Respiratory COVID-19 PCR positive | 288 (100) |
| Respiratory co-infections | 9 (3.1) |
| Human rhinovirus | 3 (1.0) |
| Streptococcus A | 3 (1.0) |
| Adenovirus | 1 (0.3) |
| Streptococcus pneumonia | 1 (0.3) |
| Haemophilus influenzae | 1 (0.3) |
| Pharmacological treatment | |
| Hydroxychloroquine | 17 (5.9) |
| Other antibiotics | 48 (16.6) |
| Azithromycin | 2 (0.7) |
| Lopinavir/Ritonavir | 0 (0) |
| Tocilizumab | 0 (0) |
| Respiratory support | |
| Invasive respiratory support | 0 (0) |
| Non-invasive respiratory support (high flow) | 4 (1.4) |
| Length of hospital stay (days) | 3.3 |
| Death | 0 (0) |
Results expressed as the number of children (%), or mean value ± SD, or median [iqr].